GLPwatch

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

NCT07202247 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether time-restricted eating, a GLP1 receptor agonist, or a heart-healthy diet can improve heart and metabolic health in men with prostate cancer who are undergoing androgen deprivation therapy.

Status Recruiting Currently enrolling participants.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) prevention study
Participants 60 people Planned (estimated).
Who can join Ages 30–79 · male only
Timeline Started 2026-01 · est. completion 2028-04
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07202247 ↗

Description as written by the study sponsor.

This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on heart and blood vessel health (cardiovascular system) and how the body processes food for energy (metabolic system) in prostate cancer patients undergoing androgen deprivation therapy (ADT). Prostate cancer patients who are receiving hormonal therapy (ADT) are at an increased risk of cardiovascular disease. This is thought to be due to treatment-related metabolic changes which may result in increased weight, body fat, insulin resistance and an increased risk of heart attack, stroke or other heart and blood vessel problems. TRE (also known as intermittent fasting) is an eating plan that alternates between fasting and non-fasting periods. This approach limits calorie intake to a specific window of time each day. GLP1-RAs, semaglutide and tirzepatide are in a class of medications called incretin mimetics. They work by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. They also slow the movement of food through the stomach and may decrease appetite and cause weight loss. The AHA HHD guidelines may be an effective method to help people learn about following a heart healthy eating plan. This may lower their risk of cardiovascular disease. Metabolic interventions, TRE and GLP1-RA, may be more effective than an AHA HHD intervention alone in improving cardiovascular and metabolic health in prostate cancer patients undergoing ADT.

Treatments tested

Main thing measuredChanges in the 10-year risk of cardiovascular disease
SponsorCity of Hope Medical Center
Conditions studiedProstate Carcinoma, Recurrent Prostate Carcinoma
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07202247 ↗